Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niket Shah

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Cureus|May 8, 2026
Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized TreatmentSuhail Sapkota, Niket Shah, Maha Bayya, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisSai Sushrutha Mudupula Vemula, Faiza Kamal, Lucas Fernet, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal DysfunctionShreya Motkur, Sai Sushrutha Mudupula Vemula, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisSai Sushrutha Mudupula Vemula, Faiza Kamal, Lucas Fernet, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal DysfunctionShreya Motkur, Sai Sushrutha Mudupula Vemula, Niket Shah, et al.
Cureus|June 15, 2026
Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic ConsiderationsSuhail Sapkota, Alfarooq Alshaikhli, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
EPR26-181: Racial and Ethnic Demographic Reporting in Studies Cited by the NCCN Testicular Cancer Guidelines: An Evidence AuditSuhail Sapkota, Sai Sushrutha Mudupula Vemula, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic CentersSai Sushrutha Mudupula Vemula, Safa Afridi, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 31, 2026
HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic CentersSai Sushrutha Mudupula Vemula, Safa Afridi, Niket Shah, et al.
Annals of Surgery|January 22, 2026
Beyond Binary Mortality Endpoints: The T-MOD PD Framework (Timing-Mechanism-Opportunity-Disease) for Phenotype-Specific Root Cause Analysis of Mortality after Pancreatoduodenectomy A Retrospective Observational Cohort StudyAmir M Parray, Niket Shah, Sohan Lal Solanki, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cureus|May 8, 2026
Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized TreatmentSuhail Sapkota, Niket Shah, Maha Bayya, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisSai Sushrutha Mudupula Vemula, Faiza Kamal, Lucas Fernet, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal DysfunctionShreya Motkur, Sai Sushrutha Mudupula Vemula, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
HSR26-234: Real-World and Clinical Outcomes of Immunotherapy-Based Regimens Versus Tyrosine Kinase Inhibitor Monotherapy in First-Line Metastatic Papillary Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisSai Sushrutha Mudupula Vemula, Faiza Kamal, Lucas Fernet, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal DysfunctionShreya Motkur, Sai Sushrutha Mudupula Vemula, Niket Shah, et al.
Cureus|June 15, 2026
Management of Acute Myeloid Leukemia in a Dialysis-Dependent Patient: A Case Report, Literature Review, and Therapeutic ConsiderationsSuhail Sapkota, Alfarooq Alshaikhli, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
EPR26-181: Racial and Ethnic Demographic Reporting in Studies Cited by the NCCN Testicular Cancer Guidelines: An Evidence AuditSuhail Sapkota, Sai Sushrutha Mudupula Vemula, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic CentersSai Sushrutha Mudupula Vemula, Safa Afridi, Niket Shah, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 31, 2026
HSR26-207: Real-World Survival and Toxicity Outcomes of Tarlatamab in Relapsed or Refractory Small-Cell Lung Cancer: A Multicenter TriNetX Analysis Across Academic and Non-Academic CentersSai Sushrutha Mudupula Vemula, Safa Afridi, Niket Shah, et al.
Annals of Surgery|January 22, 2026
Beyond Binary Mortality Endpoints: The T-MOD PD Framework (Timing-Mechanism-Opportunity-Disease) for Phenotype-Specific Root Cause Analysis of Mortality after Pancreatoduodenectomy A Retrospective Observational Cohort StudyAmir M Parray, Niket Shah, Sohan Lal Solanki, et al.
Pageof 4